300482.SZ
万孚生物
SZSE · Healthcare · C 制造业 · CN
CNY 16.00
−8.05%Year over year
Reported trailing growth
- Revenue
- -37.8%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +385.0%
- Operating cash flow
- +732.5%
Forward estimates
Based on analyst estimates
- Revenue
- -75.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -28.4%
- EBITDA
- -54.5%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -47.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026